FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200582004> ?p ?o ?g. }

• W4200582004 endingPage "638" @default.
• W4200582004 startingPage "629" @default.
• W4200582004 abstract "Globally, HIV-related adolescent deaths have increased about 50%, especially for those who are vertically infected. This could be driven by archived drug resistance mutations (DRMs) as children grow up, which might jeopardize antiretroviral therapy (ART). Our objective was to compare HIV-1 genotypic variation between plasma RNA and proviral DNA of vertically infected adolescents (aged 10-19 years) failing ART.A comparative study was conducted in 2019 among 296 adolescents with perinatal HIV infection (ALPHI) failing ART in health facilities of the Centre Region of Cameroon. The WHO clinical stage, CD4 count and plasma viral load (PVL) were measured. For those failing ART (PVL ≥ 1000 copies/mL), RNA (plasma) and proviral DNA (buffy coat) were sequenced in the pol gene at Chantal BIYA International Reference Centre (CIRCB), Yaoundé, Cameroon. HIV-1 subtypes and DRMs were interpreted using Stanford HIVdb v.8.8 and MEGA-X.Of the 30% (89/296) failing ART, 81 had both RNA and DNA sequences generated and three were excluded for APOBEC mutations: the mean age was 16 ± 3 years; female-to-male ratio was 3:5; median PVL was 46 856 copies/mL [interquartile range (IQR): 19 898-271 410]; median CD4 count was 264 cells/μL (IQR: 131-574); and 42% were at WHO clinical stage 3/4. Subtype concordance between RNA and DNA viral strains was 100%, with CRF02_AG being predominant (65%) and two potential new recombinants found (A1/G/K; F1/G). Adolescents with DRMs were significantly higher in plasma than in proviral DNA (92% vs. 86%, p < 0.0001). Prevalent DRMs by drug class (RNA vs. DNA respectively) were at position M184 (74% vs. 67%) for nucleoside reverse transcriptase inhibitors (NRTIs), K103 (63% vs. 59%) for non-NRTIs, and V82, L76 and M46 (2% vs. 2%) for protease inhibitors. A total of 35% (27/78) of adolescents had concordant DRM profiles in RNA and DNA, while 27% (21/78) had DRMs only in proviral DNA. The presence of archived DRMs was associated with advanced clinical stage 3/4 (OR = 0.14, p = 0.0003) and PVL < 5 Log (Copies/mL) (OR: 4.88, p = 0.006).Although plasma RNA remains more sensitive for detecting HIV-1 DRMs, about a quarter of ALPHI experiencing ART failure in an African setting might have archived DRMs in viral reservoirs, indicating clinically occult resistance. Thus, to ensure effective ART success, proviral DNA profiling (alongside RNA genotyping) would provide additional DRMs for adolescents with advanced clinical stages and/or moderate PVL." @default.
• W4200582004 created "2021-12-31" @default.
• W4200582004 creator A5003964599 @default.
• W4200582004 creator A5004858539 @default.
• W4200582004 creator A5006906812 @default.
• W4200582004 creator A5007451565 @default.
• W4200582004 creator A5013988397 @default.
• W4200582004 creator A5023984688 @default.
• W4200582004 creator A5025056461 @default.
• W4200582004 creator A5025765005 @default.
• W4200582004 creator A5050720946 @default.
• W4200582004 creator A5052368236 @default.
• W4200582004 creator A5054896620 @default.
• W4200582004 creator A5057199054 @default.
• W4200582004 creator A5058021222 @default.
• W4200582004 creator A5066001410 @default.
• W4200582004 creator A5066850832 @default.
• W4200582004 creator A5071504344 @default.
• W4200582004 creator A5076980268 @default.
• W4200582004 creator A5078087795 @default.
• W4200582004 creator A5078478462 @default.
• W4200582004 creator A5084242627 @default.
• W4200582004 creator A5084589140 @default.
• W4200582004 creator A5091721224 @default.
• W4200582004 date "2021-12-23" @default.
• W4200582004 modified "2023-10-17" @default.
• W4200582004 title "Archiving of mutations in HIV‐1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP‐READY study" @default.
• W4200582004 cites W1872038042 @default.
• W4200582004 cites W1964875148 @default.
• W4200582004 cites W1974951626 @default.
• W4200582004 cites W1978030756 @default.
• W4200582004 cites W1983182061 @default.
• W4200582004 cites W1983463888 @default.
• W4200582004 cites W1983504410 @default.
• W4200582004 cites W2004378719 @default.
• W4200582004 cites W2045381307 @default.
• W4200582004 cites W2057321665 @default.
• W4200582004 cites W2109046728 @default.
• W4200582004 cites W2133758885 @default.
• W4200582004 cites W2142058704 @default.
• W4200582004 cites W2164994788 @default.
• W4200582004 cites W2169210789 @default.
• W4200582004 cites W2170231953 @default.
• W4200582004 cites W2204494731 @default.
• W4200582004 cites W2408035212 @default.
• W4200582004 cites W2470418554 @default.
• W4200582004 cites W2482697111 @default.
• W4200582004 cites W2616782359 @default.
• W4200582004 cites W2768010284 @default.
• W4200582004 cites W2854053177 @default.
• W4200582004 cites W3145717752 @default.
• W4200582004 doi "https://doi.org/10.1111/hiv.13220" @default.
• W4200582004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34951111" @default.
• W4200582004 hasPublicationYear "2021" @default.
• W4200582004 type Work @default.
• W4200582004 citedByCount "3" @default.
• W4200582004 countsByYear W42005820042022 @default.
• W4200582004 countsByYear W42005820042023 @default.
• W4200582004 crossrefType "journal-article" @default.
• W4200582004 hasAuthorship W4200582004A5003964599 @default.
• W4200582004 hasAuthorship W4200582004A5004858539 @default.
• W4200582004 hasAuthorship W4200582004A5006906812 @default.
• W4200582004 hasAuthorship W4200582004A5007451565 @default.
• W4200582004 hasAuthorship W4200582004A5013988397 @default.
• W4200582004 hasAuthorship W4200582004A5023984688 @default.
• W4200582004 hasAuthorship W4200582004A5025056461 @default.
• W4200582004 hasAuthorship W4200582004A5025765005 @default.
• W4200582004 hasAuthorship W4200582004A5050720946 @default.
• W4200582004 hasAuthorship W4200582004A5052368236 @default.
• W4200582004 hasAuthorship W4200582004A5054896620 @default.
• W4200582004 hasAuthorship W4200582004A5057199054 @default.
• W4200582004 hasAuthorship W4200582004A5058021222 @default.
• W4200582004 hasAuthorship W4200582004A5066001410 @default.
• W4200582004 hasAuthorship W4200582004A5066850832 @default.
• W4200582004 hasAuthorship W4200582004A5071504344 @default.
• W4200582004 hasAuthorship W4200582004A5076980268 @default.
• W4200582004 hasAuthorship W4200582004A5078087795 @default.
• W4200582004 hasAuthorship W4200582004A5078478462 @default.
• W4200582004 hasAuthorship W4200582004A5084242627 @default.
• W4200582004 hasAuthorship W4200582004A5084589140 @default.
• W4200582004 hasAuthorship W4200582004A5091721224 @default.
• W4200582004 hasConcept C104317684 @default.
• W4200582004 hasConcept C119060515 @default.
• W4200582004 hasConcept C126322002 @default.
• W4200582004 hasConcept C135763542 @default.
• W4200582004 hasConcept C142462285 @default.
• W4200582004 hasConcept C14500911 @default.
• W4200582004 hasConcept C159047783 @default.
• W4200582004 hasConcept C160798450 @default.
• W4200582004 hasConcept C203014093 @default.
• W4200582004 hasConcept C2522874641 @default.
• W4200582004 hasConcept C2776408679 @default.
• W4200582004 hasConcept C2993143319 @default.
• W4200582004 hasConcept C3013748606 @default.
• W4200582004 hasConcept C54355233 @default.
• W4200582004 hasConcept C71924100 @default.
• W4200582004 hasConcept C86803240 @default.
• W4200582004 hasConceptScore W4200582004C104317684 @default.

• next